Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS.
Antiretroviral therapy (ART) has modified the outcome of patients with HIV infection, providing virological control and reducing mortality. However, there are several reasons as to why patients may discontinue their antiretroviral therapy, with adverse events being one of the main reasons reported in the literature. This is a case-control nested in a cohort of people living with HIV/AIDS, conducted to identify the incidence of ART modification due to adverse events and the associated factors, in two referral services in Recife, Brazil, between 2011 and 2014. Of the modifications occurred in the first year of ART, 25.7% were driven by adverse events. The median time elapsed between initiating ART and the first modification due to adverse events was 70.5 days (95% CI: 26-161 days). The main adverse events were dermatological, neuropsychiatric and gastrointestinal. Dermatological events were the earliest to appear after initiating ART. Efavirenz was the most prescribed and most modified drug during the study period. The group of participants who used zidovudine, lamivudine, and efavirenz had a 2-fold greater chance (adjusted OR: 2.16 95% CI: 1.28-3.65) of switching ART due to adverse events when compared to the group that used tenofovir with lamivudine and efavirenz.
['Azevedo|Larissa Negromonte|LN|', 'Ximenes|Ricardo Arraes de Alencar|RAA|', 'Monteiro|Polyana|P|', 'Montarroyos|Ulisses Ramos|UR|', 'Miranda-Filho|Demócrito de Barros|DB|']
D000163:Acquired Immunodeficiency Syndrome D000293:Adolescent D000328:Adult D000480:Alkynes D019380:Anti-HIV Agents D023241:Antiretroviral Therapy, Highly Active D048588:Benzoxazines D001938:Brazil D003521:Cyclopropanes D004338:Drug Combinations D005260:Female D006801:Humans D053208:Kaplan-Meier Estimate D019259:Lamivudine D016015:Logistic Models D061466:Lopinavir D008297:Male D008875:Middle Aged D012307:Risk Factors D019438:Ritonavir D000068698:Tenofovir D013997:Time Factors D055815:Young Adult D015215:Zidovudine
Antiretroviral therapy Adverse events. Efavirenz Zidovudine Tenofovir